PERSPECTIVE: Beyond the GH–IGF-1 axis: a network perspective integrating clinical observations and mechanistic insights
Endocrine Connections · 01.07.2026 · 15 (7)
DOI: 10.1530/ec-26-0317 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Connections, online erschienen am 19.06.2026. Verfasst von Go Yoshimichi. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Shinbeppu Hospital , Beppu, Oita, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Obesity encompasses a heterogeneous group of conditions that include not only simple obesity, but also genetic and endocrine disorders. The growth hormone (GH)–insulin-like growth factor 1 (IGF-1) axis plays a central role in body composition, insulin sensitivity, and metabolic regulation. We encountered three patients in whom the clinical courses highlighted distinct interactions between obesity and the GH–IGF-1 axis.
Methods
We reviewed three representative cases. Case 1 involved acromegaly improved by the peroxisome proliferator-activated receptor-α (PPAR-α) agonist pemafibrate. Case 2 involved Prader–Willi syndrome (PWS) with severe obesity treated using dulaglutide. Case 3 involved severe obesity managed with behavioral therapy. Clinical characteristics and therapeutic responses were analyzed.
Results
In case 1, pemafibrate administration resulted in a marked and sustained reduction in IGF-1 levels despite ongoing lanreotide therapy, suggesting a potential hepatic or pituitary interaction between PPAR-α signaling and GH–IGF-1 regulation. In case 2, dulaglutide induced weight loss and reduced insulin requirements in a patient with PWS, a condition characterized by high levels of ghrelin. The therapeutic effect may involve modulation of ghrelin, an upstream regulator of GH secretion. In case 3, a patient with a body mass index of 50.7 kg/m2, behavioral therapy stabilized metabolic deterioration, even though GH and IGF-1 levels remained low after weight reduction, suggesting mechanisms independent of the GH–IGF-1 axis.
Conclusion
These findings support a conceptual shift from a linear GH–IGF-1 axis to an integrated GH–IGF-1 network that connects peripheral signals, hypothalamic regulation, and higher brain functions, offering a novel framework for personalized obesity management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Shinbeppu Hospital , Beppu, Oita, Japan.
ORCID-Profile: Go Yoshimichi
Zitieren
APA
Yoshimichi, G. (2026). PERSPECTIVE: Beyond the GH–IGF-1 axis: a network perspective integrating clinical observations and mechanistic insights. Endocrine Connections, 15(7). https://doi.org/10.1530/ec-26-0317
Vancouver
Yoshimichi G. PERSPECTIVE: Beyond the GH–IGF-1 axis: a network perspective integrating clinical observations and mechanistic insights. Endocrine Connections. 2026;15(7). doi:10.1530/ec-26-0317
BibTeX
@article{Yoshimichi2026,
author = {Yoshimichi, Go},
title = {PERSPECTIVE: Beyond the GH–IGF-1 axis: a network perspective integrating clinical observations and mechanistic insights},
journal = {Endocrine Connections},
year = {2026},
volume = {15},
number = {7},
doi = {10.1530/ec-26-0317}
}
EUVIMED